Oncology & Cancer

Drug reprograms immune responses to target glioblastoma

Investigators from Northwestern University Feinberg School of Medicine and The University of Texas MD Anderson Cancer Center have discovered that using a novel drug to target the STING pathway in glioblastoma reprogrammed ...

Medications

Anlotinib plus STUPP: A new hope for glioblastoma patients

Glioblastoma multiforme (GBM) is among the most aggressive forms of brain tumors, with few effective treatment options and a bleak prognosis. The current standard of care (SOC), known as the STUPP regimen, includes surgical ...

Oncology & Cancer

Knocking out deadly brain cancer with a dual therapy

Glioblastoma is an often fatal form of brain cancer, with only 5% of patients surviving beyond five years. The cancer is difficult to treat and almost always becomes resistant to treatment. As a result, recurrence of glioblastoma ...

Oncology & Cancer

Scientists discover new immunosuppressive mechanism in brain cancer

The Wistar Institute assistant professor Filippo Veglia, Ph.D., and team, have discovered a key mechanism of how glioblastoma—a serious and often fatal brain cancer—suppresses the immune system so that the tumor can grow ...

page 3 from 32